%0 Journal Article %1 Yung:2000:Br-J-Cancer:10944597 %A Yung, W K %A Albright, R E %A Olson, J %A Fredericks, R %A Fink, K %A Prados, M D %A Brada, M %A Spence, A %A Hohl, R J %A Shapiro, W %A Glantz, M %A Greenberg, H %A Selker, R G %A Vick, N A %A Rampling, R %A Friedman, H %A Phillips, P %A Bruner, J %A Yue, N %A Osoba, D %A Zaknoen, S %A Levin, V A %D 2000 %J Br J Cancer %K temozolomide %N 5 %P 588-593 %R 10.1054/bjoc.2000.1316 %T A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse %U https://www.ncbi.nlm.nih.gov/pubmed/10944597?dopt=Abstract %V 83 %X A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 +3) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.

@article{Yung:2000:Br-J-Cancer:10944597, abstract = {A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.}, added-at = {2017-04-17T20:00:50.000+0200}, author = {Yung, W K and Albright, R E and Olson, J and Fredericks, R and Fink, K and Prados, M D and Brada, M and Spence, A and Hohl, R J and Shapiro, W and Glantz, M and Greenberg, H and Selker, R G and Vick, N A and Rampling, R and Friedman, H and Phillips, P and Bruner, J and Yue, N and Osoba, D and Zaknoen, S and Levin, V A}, biburl = {https://www.bibsonomy.org/bibtex/2c209504dfafd38653f6d9f6fe410cd55/marcsaric}, description = {A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. - PubMed - NCBI}, doi = {10.1054/bjoc.2000.1316}, interhash = {90b15695997bc48aee8a567f63f9ced4}, intrahash = {c209504dfafd38653f6d9f6fe410cd55}, journal = {Br J Cancer}, keywords = {temozolomide}, month = sep, number = 5, pages = {588-593}, pmid = {10944597}, timestamp = {2017-05-05T22:14:49.000+0200}, title = {A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse}, url = {https://www.ncbi.nlm.nih.gov/pubmed/10944597?dopt=Abstract}, volume = 83, year = 2000 }